Parameters | Inactive SLE (SLEDAI ≤ 3) | Active SLE (SLEDAI > 3) | Pvaluea |
---|---|---|---|
Total numbers (n) | 17 | 24 | N/Ab |
Age at study (years) | Â | Â | Â |
  Median | 35 | 36 | 0.474 |
  Range | 21-62 | 25-50 |  |
Sex (n) | Â | Â | Â |
  Female | 15 | 22 | N/A |
  Male | 2 | 2 | N/A |
Duration of disease (years) | Â | Â | Â |
  Median | 8 | 8 | 0.577 |
  Range | 1-22 | 1-27 |  |
Clinical parameters (mean ± SD) |  |  |  |
  White Blood Cells (x109/L) | 5.6 ± 1.8 | 4.9 ± 1.8 | 0.218 |
Clinical signs (n) | Â | Â | Â |
  Muco-cutaneous | 11 | 13 | N/A |
  Haematological | 8 | 12 | N/A |
  Neurological/Psychiatric | - | 5 | N/A |
  Serositis | - | 6 | N/A |
  Renal | 6 | 20 | N/A |
  Joint | 12 | 14 | N/A |
SLE activity (mean ± SD [range]) |  |  |  |
  SLEDAI score | 0.4 ± 0.2 [0-2] | 9.1 ± 3.8 [4-18]*** | <0.0001 |
B-cell subsets (mean ± SEM [range], x10 6 /L) |  |  |  |
  Total CD19+ B cells | 554.2 ± 121.9 [54-2077] | 319.3 ± 73.9 [6-1303] | 0.0585 |
  CD27- naive B cells | 398.6 ± 104.1 [17.9-1757] | 217.1 ± 62.1 [0.7-1205]* | 0.0403 |
  Overall CD27+ B cells | 146.2 ± 22.7 [35.1-323.2] | 96.6 ± 16.8 [5.3-292.8] | 0.0585 |
  CD27+ memory B cells | 127.5 ± 20.1 [30.3-273.6] | 82.8 ± 15.2 [1.9-279.3] | 0.0534 |
  CD27high plasma B cells | 19 ± 3.3 [4.9-49.6] | 13.9 ± 2.6 [0.9-44.2] | 0.0879 |
Treatment (n) | Â | Â | Â |
   None | 4 | 1 | N/A |
   Prednisolone | 5 | 20 | N/A |
   Azathioprine | 8 | 19 | N/A |
   Methotrexate | 2 | 1 | N/A |
   Hydroxychloroquine | 6 | 7 | N/A |
   Mycophenolate Mofetil | 2 | 3 | N/A |
   Cyclophosphamide | - | 2 | N/A |
   Leflunomide | - | 1 | N/A |